Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Abbott Laboratories has made headlines once again, this time for a bold push into cancer diagnostics through its proposed $21 billion acquisition of Exact Sciences.</li><li>The deal, which values Exact at $105 per share in cash and represents a 51% premium over its last closing price, is poised to be the largest healthcare M&A deal in two years and the biggest ever in the diagnostics space.</li><li>Slated to close in Q2 2026, the transaction marks Abbott’s strategic expansion beyond glucose monitoring and cardiovascular devices into oncology testing—a market the company had eyed for years.</li></ul>

Abbott Laboratories has made headlines once again, this time for a bold push into cancer diagnostics through its proposed $21 billion acquisition of Exact Sciences.The deal, which values Exact at $105 per share in cash and represents a 51% premium over its last closing price, is poised to be the largest healthcare M&A deal in two years and the biggest ever in the diagnostics space.Slated to close in Q2 2026, the transaction marks Abbott’s strategic expansion beyond glucose monitoring and cardiovascular devices into oncology testing—a market the company had eyed for years.

Abbott Labs' Exact Sciences Acquisition: What Could Go Right In This $21 Billion Cancer Play?

<ul><li>Abbott Laboratories' second quarter earnings report for 2025 highlighted a mixed performance across its diverse business segments.</li><li>The company demonstrated solid sales growth of 7.5% year-over-year excluding COVID testing sales, with an adjusted earnings per share (EPS) of $1.26, an 11% increase from the previous year, surpassing consensus expectations.</li><li>In its Nutrition segment, Abbott saw a 3.5% increase in sales driven largely by a robust demand for its Ensure and Glucerna brands.</li></ul>

Abbott Laboratories' second quarter earnings report for 2025 highlighted a mixed performance across its diverse business segments.The company demonstrated solid sales growth of 7.5% year-over-year excluding COVID testing sales, with an adjusted earnings per share (EPS) of $1.26, an 11% increase from the previous year, surpassing consensus expectations.In its Nutrition segment, Abbott saw a 3.5% increase in sales driven largely by a robust demand for its Ensure and Glucerna brands.

Abbott Laboratories: Is The Growth in Continuous Glucose Monitoring (CGM) & Ketone Monitoring Here To Stay?

<ul><li>Abbott Laboratories recently shared its first quarter 2025 earnings results, revealing a strong performance amidst a challenging global environment influenced by new tariff policies and ongoing economic uncertainties.</li><li>Abbott's diversified model and strategic framework contribute to the company's operational resilience, as evidenced by its ability to meet growth objectives and deliver high single-digit sales growth alongside double-digit earnings per share (EPS) growth.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Abbott Laboratories recently shared its first quarter 2025 earnings results, revealing a strong performance amidst a challenging global environment influenced by new tariff policies and ongoing economic uncertainties.Abbott's diversified model and strategic framework contribute to the company's operational resilience, as evidenced by its ability to meet growth objectives and deliver high single-digit sales growth alongside double-digit earnings per share (EPS) growth.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Abbott Laboratories Expansion Play: Can Global Growth & Local Manufacturing Drive the Next Surge?

<ul><li>Abbott Laboratories delivered a solid financial performance in the fourth quarter of 2024, reflecting a continuation of robust growth trends observed throughout the year.</li><li>Excluding COVID-19 testing, the company reported a strong sales growth of 10%, contributing to a full-year increase of 9.5%.</li><li>This surge was driven by significant progress across several business segments, particularly Adult Nutrition and Medical Devices, including continuous glucose monitoring systems.</li></ul>

Abbott Laboratories delivered a solid financial performance in the fourth quarter of 2024, reflecting a continuation of robust growth trends observed throughout the year.Excluding COVID-19 testing, the company reported a strong sales growth of 10%, contributing to a full-year increase of 9.5%.This surge was driven by significant progress across several business segments, particularly Adult Nutrition and Medical Devices, including continuous glucose monitoring systems.

Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating!

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<ul>
<li>A group of shareholders raised around US$530m in <a href="https://www.smartkarma.com/entities/mankind-pharma-ltd" target="_blank" data-smartkarma-citation="entities:36389:1" rel="noopener">Mankind Pharma</a>(MP) IPO in May 2023. The pre-IPO shareholders will be released from their lockup soon.</li>
<li>MP is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.</li>
<li>In this note, we will talk about the lock-up dynamics and recent updates.</li>
</ul>


A group of shareholders raised around US$530m in Mankind Pharma(MP) IPO in May 2023. The pre-IPO shareholders will be released from their lockup soon.
MP is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
In this note, we will talk about the lock-up dynamics and recent updates.


Mankind Pharma Lock-Up - A US$1.1bn+ Lockup Release

United States

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbott Laboratories (ABT US)

Abbott Labs' Exact Sciences Acquisition: What Could Go Right In This $21 Billion Cancer Play?

Abbott Laboratories has made headlines once again, this time for a bold push into cancer diagnostics through its proposed $21 billion acquisition...

Baptista Research

Abbott Laboratories: Is The Growth in Continuous Glucose Monitoring (CGM) & Ketone Monitoring Here To Stay?

Abbott Laboratories' second quarter earnings report for 2025 highlighted a mixed performance across its diverse business segments. The company...

Baptista Research

Abbott Laboratories Expansion Play: Can Global Growth & Local Manufacturing Drive the Next Surge?

Abbott Laboratories recently shared its first quarter 2025 earnings results, revealing a strong performance amidst a challenging global...

Baptista Research

Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating!

Abbott Laboratories delivered a solid financial performance in the fourth quarter of 2024, reflecting a continuation of robust growth trends...

Baptista Research

Mankind Pharma Lock-Up - A US$1.1bn+ Lockup Release

The two pre-IPO investors have launched a block to sell around US$591m worth of Mankind Pharma shares. Since the lockup on the shares expired not...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)